ArticleVaccine2026
An evaluation of a multifaceted training program to build National Immunization Technical Advisory Group (NITAG) capacity for making evidence-based immunization policy.
Article in Vaccine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSince January 2022, regional National Immunization Technical Advisory Group (NITAG) workshops have been held for more than 50 countries to strengthen participants' understanding of NITAG functions, basic vaccinology, and the ability to make evidence-based decisions on vaccines. A midterm evaluation was conducted in select countries to assess impact and guide future workshop enhancements, ensuring content is tailored to country-specific needs and practical application of NITAG functions.
methodsAn online questionnaire was conducted between December 2023 and February 2024, targeting NITAGs from 12 workshops held 6-24 months earlier in the African (AFR) and Eastern Mediterranean (EMR) Regions. Each country submitted one consolidated response covering five sections: general information, basic NITAG functions, the evidence-to-recommendation (EtR) process, vaccinology, and training agenda.
resultsOf 28 NITAGs trained between February 2022 and August 2023, 21 (75%; 13/15 AFR, 8/13 EMR) participated in the evaluation survey. Most NITAGs (76%) participated in multi-country workshops, with median 10 individuals (range 2-22) per country. Following the workshops, 67% of NITAGs developed or revised key documents (e.g., standard operating procedures) and 50% updated other policies (e.g., conflict of interest). Among 19 NITAGs that attended the full EtR training, 11 completed the vaccine-specific EtR process started during the workshop (6 also applied the EtR process to additional vaccines). Among 15 NITAGs that attended vaccinology sessions, all reported applying the knowledge in their work. Respondents requested more time for evidence analysis and synthesis during future trainings.
conclusionsPost training evaluation of NITAG capacity-building workshops showed positive and sustained impact for operations, vaccinology, and the application of the EtR process for a vaccine policy question. Our findings suggest future workshops may be enhanced by requiring pre-training eLearning modules and strengthening indicators to monitor training quality and outcomes. Such improvements may help to reinforce NITAG capacity for evidence-informed immunization policy-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.